Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism?
paper
Cited
Public
Unavailable
- Authors
- Egli, Mark
- Year
- 2005
- Journal
- Addiction biology
- PMID
- 16318951
- DOI
- 10.1080/13556210500314550
Evaluating medications in animal laboratory paradigms can reveal whether the compound is effective in an established alcoholism model, at clinically relevant doses and exposure conditions, when administered orally (or transdermally) and without serious limiting side effects. Positive outcomes constitute a possible discovery for relevance to alcoholism and, under favorable marketing conditions, encourage further development. Medication testing using animal models of alcoholism might also guide clinical testing by discriminating clinically effective from clinically ineffective compounds. This ability rests on whether there are tests or, more reasonably, batteries of tests having this discriminative ability. The present paper examines this possibility. Effects of naltrexone and acamprosate in animal paradigms which model behavioral aspects of alcoholism are reviewed and compared with the effects of compounds which have limited effects in alcoholics. It is not clear at present whether any single paradigm or combination of paradigms differentiates clinically effective from clinically limited compounds. Steps are suggested to improve the use of preclinical laboratory tests to predict which compounds are likely to be effective medications for reducing drinking and sustaining abstinence in human alcoholics.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Genetic research: who is at risk for alcoholism. | 2010 | 23579937 |
| The complexity of alcohol drinking: studies in rodent genetic models. | 2010 | 20552264 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Stress-related neuropeptide systems as targets for treatment of alcohol addiction: A clinical perspective. | Heilig M | β | 2023 | β |
| The life and times of endogenous opioid peptides: Updated understanding of synthesis, spatiotemporal dynamics, and the clinical impact in alcohol use disorder. | Margolis EB et al. | β | 2023 | β |
| Do behavioral pharmacology findings predict clinical trial outcomes? A proof-of-concept in medication development for alcohol use disorder. | Ray LA et al. | β | 2021 | β |
| Five Priority Areas for Improving Medications Development for Alcohol Use Disorder and Promoting Their Routine Use in Clinical Practice. | Litten RZ et al. | β | 2020 | β |
| Tetracycline derivatives reduce binge alcohol consumption in High Drinking in the Dark mice. | Crabbe JC et al. | β | 2020 | β |
| Dopamine and opioid systems adaptation in alcoholism revisited: Convergent evidence from positron emission tomography and postmortem studies. | Hansson AC et al. | β | 2019 | β |
| Evaluation of mifepristone effects on alcohol-seeking and self-administration in baboons. | Holtyn AF et al. | β | 2019 | β |
| Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice. | Huynh N et al. | β | 2019 | β |
| Advancing Pharmacotherapy Development from Preclinical Animal Studies. | Egli M | β | 2018 | β |
| Overcoming the "Valley of Death" in Medications Development for Alcohol Use Disorder. | Ray LA et al. | β | 2018 | β |
| An assessment of the utilization of the preclinical rodent model literature in clinical trials of putative therapeutics for the treatment of alcohol use disorders. | Barajaz AM et al. | β | 2017 | β |
| Baclofen and naltrexone effects on alcohol self-administration: Comparison of treatment initiated during abstinence or ongoing alcohol access in baboons. | Holtyn AF et al. | β | 2017 | β |
| Further characterization of the GlyT-1 inhibitor Org25935: anti-alcohol, neurobehavioral, and gene expression effects. | LidΓΆ HH et al. | β | 2017 | β |
| High Drinking in the Dark (HDID) mice are sensitive to the effects of some clinically relevant drugs to reduce binge-like drinking. | Crabbe JC et al. | β | 2017 | β |
| Multi-modal MRI classifiers identify excessive alcohol consumption and treatment effects in the brain. | Cosa A et al. | β | 2017 | β |
| The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target? | Pomrenze MB et al. | β | 2017 | β |
| The glucagon-like peptide 1 receptor agonist Exendin-4 decreases relapse-like drinking in socially housed mice. | Thomsen M et al. | β | 2017 | β |
| Considerations in the Evaluation of Potential Efficacy of Medications for Alcohol and Drug Use Disorders: An Editorial. | Egli M et al. | β | 2016 | β |
| Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development. | Litten RZ et al. | β | 2016 | β |
| Preclinical Medication Development: New Targets and New Drugs. | Kasten CR et al. | β | 2016 | β |
| The Need for Treatment Responsive Translational Biomarkers in Alcoholism Research. | Heilig M et al. | β | 2016 | β |
| Binge alcohol drinking elicits persistent negative affect in mice. | Lee KM et al. | β | 2015 | β |
| Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence. | Bell RL et al. | β | 2015 | β |
| Postdependent state in rats as a model for medication development in alcoholism. | Meinhardt MW et al. | β | 2015 | β |
| Preclinical evidence implicating corticotropin-releasing factor signaling in ethanol consumption and neuroadaptation. | Phillips TJ et al. | β | 2015 | β |
| The importance of animals in advancing research on alcohol use disorders. | Helms CM et al. | β | 2015 | β |
| Baclofen effects on alcohol seeking, self-administration and extinction of seeking responses in a within-session design in baboons. | Duke AN et al. | β | 2014 | β |
| Efficacy and safety of the glycine transporter-1 inhibitor org 25935 for the prevention of relapse in alcohol-dependent patients: a randomized, double-blind, placebo-controlled trial. | de Bejczy A et al. | β | 2014 | β |
| Making organisms model human behavior: situated models in North-American alcohol research, since 1950. | Ankeny RA et al. | β | 2014 | β |
| Perspectives on the neuroscience of alcohol from the National Institute on Alcohol Abuse and Alcoholism. | Reilly MT et al. | β | 2014 | β |
| Rodent models of genetic contributions to motivation to abuse alcohol. | Crabbe JC | β | 2014 | β |
| The effects of varenicline on alcohol seeking and self-administration in baboons. | Kaminski BJ et al. | β | 2014 | β |
| Use of animal models of alcohol-related behavior. | Crabbe JC | β | 2014 | β |
| Effects of naltrexone on post-abstinence alcohol drinking in C57BL/6NCRL and DBA/2J mice. | Tomie A et al. | β | 2013 | β |
| Effects of the benzodiazepine GABAA Ξ±1-preferring ligand, 3-propoxy-Ξ²-carboline hydrochloride (3-PBC), on alcohol seeking and self-administration in baboons. | Kaminski BJ et al. | β | 2013 | β |
| Effects of naltrexone on alcohol drinking patterns and extinction of alcohol seeking in baboons. | Kaminski BJ et al. | β | 2012 | β |
| Medications development to treat alcohol dependence: a vision for the next decade. | Litten RZ et al. | β | 2012 | β |
| Pharmacological blockade of corticotropin-releasing hormone receptor 1 (CRH1R) reduces voluntary consumption of high alcohol concentrations in non-dependent Wistar rats. | Cippitelli A et al. | β | 2012 | β |
| Critical thoughts on current rodent models for evaluating potential treatments of alcohol addiction and withdrawal. | Ripley TL et al. | β | 2011 | β |
| Pharmacogenetic approaches to the treatment of alcohol addiction. | Heilig M et al. | β | 2011 | β |
| Ethanol consumption: how should we measure it? Achieving consilience between human and animal phenotypes. | Leeman RF et al. | β | 2010 | β |
| Genetic research: who is at risk for alcoholism. | Foroud T et al. | β | 2010 | β |
| Genetic variation and brain gene expression in rodent models of alcoholism implications for medication development. | BjΓΆrk K et al. | β | 2010 | β |
| The complexity of alcohol drinking: studies in rodent genetic models. | Crabbe JC et al. | β | 2010 | β |
| Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues. | Heilig M et al. | β | 2010 | β |
| Acute ethanol challenge inhibits glycogen synthase kinase-3beta in the rat prefrontal cortex. | Neznanova O et al. | β | 2009 | β |
| Functional CRH variation increases stress-induced alcohol consumption in primates. | Barr CS et al. | β | 2009 | β |
| Trait anxiety and ethanol: anxiolysis in high-anxiety mice and no relation to intake behavior in an addiction model. | Correia D et al. | β | 2009 | β |
| A blocker of N- and T-type voltage-gated calcium channels attenuates ethanol-induced intoxication, place preference, self-administration, and reinstatement. | Newton PM et al. | β | 2008 | β |
| Acute effects of acamprosate and MPEP on ethanol Drinking-in-the-Dark in male C57BL/6J mice. | Gupta T et al. | β | 2008 | β |
| Effects of naltrexone, duloxetine, and a corticotropin-releasing factor type 1 receptor antagonist on binge-like alcohol drinking in rats. | Ji D et al. | β | 2008 | β |
| Long-lasting tolerance to alcohol following a history of dependence. | Rimondini R et al. | β | 2008 | β |
| Modulation of voluntary ethanol consumption by beta-arrestin 2. | BjΓΆrk K et al. | β | 2008 | β |
| Targeting brain angiotensin and corticotrophin-releasing hormone systems interaction for the treatment of mood and alcohol use disorders. | Sommer WH et al. | β | 2008 | β |
| Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism. | Krishnan-Sarin S et al. | β | 2008 | β |
| Upregulation of voluntary alcohol intake, behavioral sensitivity to stress, and amygdala crhr1 expression following a history of dependence. | Sommer WH et al. | β | 2008 | β |
| 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo[1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. | Gehlert DR et al. | β | 2007 | β |
| Acute effects of naltrexone and GBR 12909 on ethanol drinking-in-the-dark in C57BL/6J mice. | Kamdar NK et al. | β | 2007 | β |
| A key role for corticotropin-releasing factor in alcohol dependence. | Heilig M et al. | β | 2007 | β |
| Imagen: implications for addiction science and science policy. | Heilig M | β | 2007 | β |
| Plasticity and impact of the central renin-angiotensin system during development of ethanol dependence. | Sommer WH et al. | β | 2007 | β |
| Preclinical and clinical pharmacology of alcohol dependence. | Tambour S et al. | β | 2007 | β |
| The effects of lamotrigine on alcohol seeking and relapse. | Vengeliene V et al. | β | 2007 | β |
| Translational research in medication development for nicotine dependence. | Lerman C et al. | β | 2007 | β |
| Genetically selected Marchigian Sardinian alcohol-preferring (msP) rats: an animal model to study the neurobiology of alcoholism. | Ciccocioppo R et al. | β | 2006 | β |
| The alcohol-preferring AA and alcohol-avoiding ANA rats: neurobiology of the regulation of alcohol drinking. | Sommer W et al. | β | 2006 | β |
| Laboratory models of alcoholism: treatment target identification and insight into mechanisms. | Lovinger DM et al. | β | 2005 | β |